✦ LIBER ✦

Cell kinetics after high dose cytosine arabinoside in patients with acute myelocytic leukemia

✍ Scribed by Colly, L. P. ;Peters, W. G. ;Arentsen-Honders, M. W. ;Willemze, R.

Publisher: Springer-Verlag
Year: 1990
Weight: 484 KB
Volume: 60
Category: Article
ISSN: 1432-0584
DOI: 10.1007/bf01720511

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Acute polyneuropathy after high dose cyt

Acute polyneuropathy after high dose cytosine arabinoside in patients with leukemia

✍ Harry Openshaw; Neal E. Slatkin; Anthony S. Stein; David R. Hinton; Stephen J. F 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 699 KB

## BACKGROUND. Peripheral nerve toxicity has been reported but is not a commonly recognized complication of high dose cytosine arabinoside (HDAC) therapy. This study was undertaken to estimate the prevalence and describe the clinical spectrum of acute polyneuropathy associated with HDAC therapy fo

High dose cytosine arabinoside (HDARAC)

High dose cytosine arabinoside (HDARAC) in refractory acute leukemia

✍ Seth A. Rudnick; Edwin C. Cadman; Robert L. Capizzi; Roland T. Skeel; Joseph R. 📂 Article 📅 1979 🏛 John Wiley and Sons 🌐 English ⚖ 415 KB 👁 2 views

Thirteen leukemic patients with disease refractory to conventional chemotherapy were treated with 1.0 to 7.5 g/m2 of Cytosine Arabinoside (Ara-C) over 29 drug cycles. Drug infusions were spaced at 12-hour intervals; a maximum of four doses was administered over 36 hours. After single dose tolerance

Sequential intermediate-dose cytosine ar

Sequential intermediate-dose cytosine arabinoside and mitoxantrone for patients with relapsed and refractory acute myelocytic leukemia

✍ Paolo Alberto Paciucci; Janet Cuttner; James F. Holland 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 389 KB 👁 2 views

Sequential mitoxantrone, daunorubicin, a

Sequential mitoxantrone, daunorubicin, and cytosine arabinoside for patients with newly diagnosed acute myelocytic leukemia

✍ Paciucci, Paolo Alberto; Cuttner, Janet; Gottlieb, Arlan; Davis, Roger B.; Marte 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 27 KB 👁 2 views

Mitoxantrone (M) is a synthetic aminoanthraquinone with anti-leukemic activity in patients with daunorubicin (D) resistant acute leukemia. The Cancer and Leukemia Group B (CALGB) has undertaken a limited access pilot study in which M, 12 mg/m2, over 30 min, daily for 3 days, and cytosine arabinoside

Mitoxantrone and high-dose cytosine arab

Mitoxantrone and high-dose cytosine arabinoside in refractory acute myelogenous leukemia

✍ Ronald S. Walters; Hagop M. Kantarjian; Michael J. Keating; William K. Plunkett; 📂 Article 📅 1988 🏛 John Wiley and Sons 🌐 English ⚖ 547 KB

Forty-four patients with a diagnosis of refractory or relapsed acute myelogenous leukemia received salvage chemotherapy with high-dose cytosine arabinosine 3 g/m2 intravenously over 2 hours every 12 hours for six doses and mitoxantrone 5 mg/m2 intravenously daily for 5 days. Overall 16 patients (36%

Sequential high-dose cytosine arabinosid

Sequential high-dose cytosine arabinoside and asparaginase in refractory acute leukemia

✍ Capizzi, Robert L. ;Cheng, Yung-Chi 📂 Article 📅 1982 🏛 John Wiley and Sons 🌐 English ⚖ 551 KB

The development of resistance to Ara-C by leukemia cells may be a multifactorial process. These include diminished rates of anabolism or increased rate of catabolism to Ara-C, competition for incorporation into DNA by higher pool size of the competing normal metabolite, dCTP and perhaps other mechan